NEW YORK (GenomeWeb News) – Fluidigm intends to significantly expand its sales staff, particularly in North America, over the next two years, President and CEO Gajus Worthington told GenomeWeb Daily News this week.

"Our goal is to quadruple the size of our US sales operations over the next two years," he said. "The goal is to get the total size of that operation to 60 people.

"The reason that we're doing it is the business has expanded dramatically, even against the backdrop of the recession, and particularly in North America," said Worthington.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.